secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269533
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones
--------------------------------------------------------------------------------

- Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.
- R&D expenses $15.3M (-$6.1M YoY); G&A $6.4M (-$1.5M YoY); total operating expense $21.7M.
- CX-2051 Phase 1 enrollment ~100 patients by Q1 2026 data update; Phase 1b combo with bevacizumab starts Q1 2026.
- CX-801 Phase 1 monotherapy biomarker data at SITC 2025; combo with KEYTRUDA dose escalation enrolling 2nd dose level.
- Appointed Rachael Lester as SVP, Chief Business Officer in October 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525269533/0001193125-25-269533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525269533/ctmx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer